Metabolome-wide association identifies ferredoxin-1 (FDX1) as a determinant of cholesterol metabolism and cardiovascular risk in Asian populations
- PMID: 40360795
- DOI: 10.1038/s44161-025-00638-w
Metabolome-wide association identifies ferredoxin-1 (FDX1) as a determinant of cholesterol metabolism and cardiovascular risk in Asian populations
Abstract
The burden of cardiovascular disease is rising in the Asia-Pacific region, in contrast to falling cardiovascular disease mortality rates in Europe and North America. Here we perform quantification of 883 metabolites by untargeted mass spectroscopy in 8,124 Asian adults and investigate their relationships with carotid intima media thickness, a marker of atherosclerosis. Plasma concentrations of 3beta-hydroxy-5-cholestenoate (3BH5C), a cholesterol metabolite, were inversely associated with carotid intima media thickness, and Mendelian randomization studies supported a causal relationship between 3BH5C and coronary artery disease. The observed effect size was 5- to 6-fold higher in Asians than Europeans. Colocalization analyses indicated the presence of a shared causal variant between 3BH5C plasma levels and messenger RNA and protein expression of ferredoxin-1 (FDX1), a protein that is essential for sterol and bile acid synthesis. We validated FDX1 as a regulator of 3BH5C synthesis in hepatocytes and macrophages and demonstrated its role in cholesterol efflux in macrophages and aortic smooth muscle cells, using knockout and overexpression models.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: K.E.W. and G.A.M. are employees of Metabolon, and P.A.S. and R.S. were employees of Metabolon. The authors do not hold stocks in Metabolon and declare no competing interests.
References
-
- Collaborators, G. Co. D. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet https://doi.org/10.1016/S0140-6736(24)00367-2 (2024). - DOI
MeSH terms
Substances
Grants and funding
- NMRC/StaR/0028/2017/MOH | National Medical Research Council (NMRC)
- MOH-000271/MOH | National Medical Research Council (NMRC)
- NMRC/PRECISE/2020/MOH | National Medical Research Council (NMRC)
- MOH-001712-01/MOH | National Medical Research Council (NMRC)
- CS-IRG - MOH-001480-00/MOH | National Medical Research Council (NMRC)
- MOH-000896-00/MOH | National Medical Research Council (NMRC)
- H17/01/a0/007/Agency for Science, Technology and Research (A*STAR)
- H18/01/a0/016/Agency for Science, Technology and Research (A*STAR)
- MOE-T2EP30122-0018/Ministry of Education - Singapore (MOE)
- MOH-000333-00/Ministry of Education - Singapore (MOE)
- MOE-000322-00/Ministry of Education - Singapore (MOE)
- MOH-001226-00/Ministry of Health -Singapore (MOH)
LinkOut - more resources
Full Text Sources
Medical